• Eli Lilly CEO Talks Coronavirus Treatment Progress: ‘This Is An Important Bridge Therapy’

    Eli Lilly CEO Talks Coronavirus Treatment Progress: 'This Is An Important Bridge Therapy'Drugmaker Eli Lilly And Co (NYSE: LLY) started a human study of a potential antibody treatment for COVID-19 patients, and CEO David Ricks said on Fox Business that it is the first of its kind.Lilly's Brand New Medicine Eli Lilly's medicine to treat COVID-19 patients is the first of its kind, as it consists of antibodies found in a recovered patient's cells. In contrast, other drugs and therapies are merely "repurposed" from other uses, Ricks said.Eli Lilly scientists collaborated with Canada-based AbCellera to engineer a treatment out of the "very best one or two" antibodies it can find out of millions of cells, the CEO said. The initial study will consist of less than 40 patients, and results are expected in a "couple of weeks," he said. Lilly's Production Timeline Eli Lilly has already started the process of ramping up production for its hopeful therapy despite it being in the early stages of testing, Ricks said.The company expects to produce 100,000 or more doses that will be available in the fall, the CEO said.During the pandemic's peak, there were around 60,000 people in a hospital in the U.S., so 100,000 could treat every person, he said.Important Treatment Before Vaccine Eli Lilly wants to study how its medicine can be used to treat people to avoid the need of going to a hospital in the first place as part of an ambulatory treatment study.The company also wants to explore later on in the summer months how its treatment can be used among those most at risk and vulnerable."This is an important bridge therapy until a vaccination could arrive and even perhaps vaccination this kind of therapy could find an important use," the CEO said.Lilly shares were trading down slightly at $152.86 at the time of publication Monday.Related Links:Moderna Doses First Participants In Phase 2 Study Of Coronavirus Vaccine53% Of Americans 'Very Likely' To Get Coronavirus Vaccine, Rasmussen ReportsEli Lilly CEO David Ricks. Benzinga file photo by Dustin Blitchok. See more from Benzinga * Making Sense Of Why Consumers Are Switching Their Grocery Store Habits * Intermediate Options Strategy With Ally Invest's Brian Overby * Impossible Foods Scores Big Win In Legal Battle With Nestle(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    from Yahoo Finance https://ift.tt/3eGhY5i

  • How to value the big four ASX banks

    maginfying glass over dollar sign

    Yesterday, I explored how some of the current issues facing the ASX banks could be impacting their ‘bankability’. But to understand how banks are valued in the first place, you need to recognise how they differ from other type of stocks. For example, unlike regular industrial stocks, banks make money from borrowing, lending and aiding the flow of money throughout the economy. This makes them highly vulnerable to the economic cycle, and as an investor you need to know when they’re out of the money.

    You need to tread carefully when using a price-to-earnings ratio (P/E) and dividend yield to gauge how attractive ASX bank shares might be. That’s because bad debts or one-off items can compromise the sustainability of bank dividends, as shareholders discovered in 2007 when they were slashed to help prop up badly needed bank capital.

    It’s also important to understand that banks require some peculiar evaluation criteria when it comes to assessing their intrinsic value and business performance. If you do want to use the P/E ratio to help value and compare one bank share against another, then it must be used alongside some bank-specific financial ratios.

    While some valuation principles are equally applicable to all companies, there are a number of complications specific to banks. These include determining leverage – due to being both borrower and lender – regulatory impact, capital expenditure and interest margins.

    Key ratios

    Net interest margin (NIM): A bank’s primary income source is the difference between the interest income from its loan book, and interest paid out to depositors. Typically expressed as a percentage of the average loans outstanding over the period under review, this is known as the ‘net interest margin’ (NIM). A high ratio indicates bank efficiency. While you won’t find it in official financial statements, most banks disclose this average somewhere near the front of their detailed annual reports.

    Cost to income ratio: Measures a bank’s operating expenses as a percentage of its total income. The lower the ratio, the better the bank is at controlling costs and most brokers prefer banks with a cost to income ratio of less than 50%.

    Bad debts ratio: Measures a bank’s provisioning for when a client can’t meet their repayments and a debt goes bad. The higher the number of bad loans, the higher you really want the net interest margin to be, otherwise it could wipe out a hefty chunk of profit.

    Return on assets: As a useful efficiency measure for banks, ROA indicates how profitable a bank is relative to its total assets. Calculated by dividing annual earnings by its total assets, ROA is displayed as a percentage – the higher the better – and should reveal how competent management is at using its assets, like mortgages to generate earnings.

    Tier 1 capital ratio: Is a litmus test of a bank’s capital strength. It’s arrived at by isolating the amount of ‘tier 1 capital’ – the highest quality capital – then identifying the proportion of ‘risk-weighted assets’. Capital ratios in the big four and Macquarie range between 10.8% and 12.2%.

    Price to book ratio: Is the value you would see if the business was liquidated and liabilities paid out. A ratio of 1 indicates shareholders can only expect a return of book value. A ratio above 1 indicates the extent to which shareholders are potentially exposed to market risk.

    Standout ASX bank shares to buy now

    Based on its forecasted pre-provision operating profit per share growth over the next 3 years, Goldman Sachs’ preferred major bank exposure is National Australia Bank Ltd (ASX: NAB). It expects NAB’s revenue momentum to remain superior to its peers, driven by its overweight exposure to SME lending. While NAB has taken the lowest provision for bad debts, at 0.38%, its credit impairment charge as a percentage of loans is also considerably lower than its peers.

    At a share price of $17.95, the bank is still trading 40% down on its 52-week high of $30.00. Goldman Sachs also reiterates a buy on Australia and New Zealand GrpLtd (ASX: ANZ) shares, which at $18.05 are still trading 38% down on their 52-week high of A$29.30.

    Based on its strong deposit franchise, Commonwealth Bank of Australia (ASX: CBA) is seen as more vulnerable to the medium-term impact of lower rates. The bank also has the highest exposure to more competitive mortgages relative to its peers. Based on a valuation that’s more expensive in relative and absolute terms, Goldman Sachs concludes that NAB and ANZ offer a more attractive entry point at current levels.

    Similarly, while Westpac Banking Corp (ASX: WBC) has demonstrated better expense control, stronger margins, and better than expected housing growth, the stock is not regarded as a buy. This is due to risk of higher investment spend, plus the risk of elevated fines and asset quality deterioration. At $17.36, Westpac shares are trading at a 42% discount to its 52-week high of $30.05.

    Market uncertainty over banks’ fortunes is reflected in buy, hold and sell consensus broker recommendations on ANZ, NAB and Westpac. However, brokers unanimously agree that Commonwealth Bank is not a buy, with 12 out of 15 seeing it as a strong sell.

    Despite the recent rally, bank share prices still suffer from a negative sentiment overhang that pre-dates COVID-19. Yet if the GFC is any proxy, the post-crisis period bodes well for the sector.

    For 5 more shares set for post-COVID-19 growth, don’t miss the free report below.

    NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!….

    Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

    One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

    Another is a diversified conglomerate trading over 40% off its high, all while offering a fully franked dividend yield over 3%…

    Plus 3 more cheap bets that could position you to profit over the next 12 months!

    See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

    CLICK HERE FOR YOUR FREE REPORT!

    More reading

    Motley Fool contributor Mark Story has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post How to value the big four ASX banks appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2Mo7FGQ

  • Canopy Growth: Things Are Worse Than Thought, Says Jefferies

    Canopy Growth: Things Are Worse Than Thought, Says JefferiesWhat is the worst thing an investor could hear from a market share leader? According to Jefferies’ analyst Owen Bennett, it is probably the need to "understand what consumers want.”And that’s just what Canopy Growth (CGC) has said. According to the analyst, the Canadian cannabis producer’s disappointing FQ4 results indicate “things are worse than thought.”Canopy's Q4 net revenue came in at C$107.9 million, well below the C$128.9 million estimate and down by 13% from the previous quarter. The enormous overall net loss of C$1.3 billion, amounted to C$3.72 per share, far worse that the Street’s expectation of C$0.59 per share. Cue investors running to the exit door and a drop of 20% in the following trading session.Bennett recently upgraded Canopy’s rating from Sell to Hold, based on the reasoning “top line pressures were better understood,” and under the impression cost saving actions were moving the company in the right direction.Pointing out the slim bull case for Canopy rested on “increased focus on cost structure and profit delivery,” the analyst believes the turnaround appears more sluggish than anticipated as evidenced by operating expenses. Instead of improving, these increased by 17% compared to the previous quarter.Additionally, looking ahead, Canopy reduced expectations, describing FY21 as a “transition year,” and taking off the table previous forecasts for when it would achieve positive adjusted EBITDA.Along with the letdown of the report, the tone coming from Canopy’s direction has not impressed Bennett, who said, “While it said it is addressing certain headwinds with a shift into value and more high THC offerings, what really concerned us was commentary around needing to "understand what consumers want", and "servicing different segments". This is just basics and an issue we flagged over 12 months ago when initiating (Canopy having a catch all brand with no segmentation) and is something that in our view should be addressed prior to legalisation, not over a year into it, and especially from a market share leader.”To this end, Bennett reiterated a Hold and has a C$22.00 (US$16) price target on Canopy shares. (To watch Bennett’s track record, click here)Most of Wall Street echoes a neutral point of view, with TipRanks analytics exhibiting Canopy Growth as a Hold. Based on 15 analysts tracked by in the last 3 months, 2 say Buy, 10 suggest Hold, while 3 recommends Sell. Meanwhile the 12-month average price target stands at C$22.44, which aligns with where the stock is currently trading. (See Canopy Growth stock analysis on TipRanks)To find good ideas for cannabis stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

    from Yahoo Finance https://ift.tt/36Ptd8M